Synairgen backer ready to pump £18-£19 million into phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £19 million to fund the development of SNG001, its investigational inhaled interferon beta treatment. The funding includes a …